Research programme: interleukin-17 receptor antagonists - HitGen

Drug Profile

Research programme: interleukin-17 receptor antagonists - HitGen

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HitGen
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Macrocyclic compounds
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Asthma; Multiple sclerosis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 02 Mar 2017 Interleukin-17 receptor inhibitors - HitGen is available for licensing as of 02 Mar 2017. http://www.hitgen.com/?page_id=7101 (HitGen pipeline, March 2017)
  • 02 Mar 2017 Early research in Rheumatoid arthritis in China (PO) before March 2017 (HitGen pipeline, March 2017)
  • 02 Mar 2017 Early research in Asthma in China (PO) before March 2017 (HitGen pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top